User:Jessica Dempsey/sandbox1
From Proteopedia
(Difference between revisions)
| Line 26: | Line 26: | ||
One way that has been researched to treat cancer with saporin is by using an amino-terminal fragment (ATF) and fusing it with saporin (SAP) <ref name="par" />. The specific ATF used was the human urokinase-type plasminogen activator (uPA) which is the ligand to the urokinase plasminogen activator receptor (uPAR). This means that uPAR will bind uPA, and if saporin is fused with uPA, it will also be bound to the uPAR. This is important because uPAR is upregulated, increasing its levels in cancer cells <ref name="par" />. With increased levels, it means that more uPA will be in the cancer cell and again more saporin since the saporin is bounded to the uPA. This particular study found that the ATF-SAP was able to get into the cancer cells and kill the cells in cancer cells. Although, with lower and undetectable levels of uPAR, there was no effect on cancer with ATF-SAP <ref name="par" />. Saporin can be bound to other molecules to make it effective for specific things in the body. Although, there need to be appropriate levels of what is being targeted, or the saporin won't be able to get to where it needs to be to achieve the goal. | One way that has been researched to treat cancer with saporin is by using an amino-terminal fragment (ATF) and fusing it with saporin (SAP) <ref name="par" />. The specific ATF used was the human urokinase-type plasminogen activator (uPA) which is the ligand to the urokinase plasminogen activator receptor (uPAR). This means that uPAR will bind uPA, and if saporin is fused with uPA, it will also be bound to the uPAR. This is important because uPAR is upregulated, increasing its levels in cancer cells <ref name="par" />. With increased levels, it means that more uPA will be in the cancer cell and again more saporin since the saporin is bounded to the uPA. This particular study found that the ATF-SAP was able to get into the cancer cells and kill the cells in cancer cells. Although, with lower and undetectable levels of uPAR, there was no effect on cancer with ATF-SAP <ref name="par" />. Saporin can be bound to other molecules to make it effective for specific things in the body. Although, there need to be appropriate levels of what is being targeted, or the saporin won't be able to get to where it needs to be to achieve the goal. | ||
| + | The study explained above has saporin being used as a chimeric toxin, which is different from that of an immunotoxin <ref name="ncbi" />. This just means that the saporin is conjugated with another carrier rather than one, such as antibodies <ref name="ncbi" />. One way that this is helpful is so that the saporin does not activate an immune response. In general, plant toxin-based chimerae have shown less immune response when compared to bacterial origin toxins <ref name="fab" />. Since there is less immune response, the body will not attack the saporin conjugates, at least not as much, and the saporin can get to the target area, most likely cancer. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 01:39, 24 April 2022
Your Heading Here (maybe something like 'Structure')
| |||||||||||
References
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
- ↑ Bolshakov AP, Stepanichev MY, Dobryakova YV, Spivak YS, Markevich VA. Saporin from Saponaria officinalis as a Tool for Experimental Research, Modeling, and Therapy in Neuroscience. Toxins (Basel). 2020 Aug 25;12(9). pii: toxins12090546. doi:, 10.3390/toxins12090546. PMID:32854372 doi:http://dx.doi.org/10.3390/toxins12090546
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 Polito L, Bortolotti M, Mercatelli D, Battelli MG, Bolognesi A. Saporin-S6: a useful tool in cancer therapy. Toxins (Basel). 2013 Oct 7;5(10):1698-722. doi: 10.3390/toxins5101698. PMID:24105401 doi:http://dx.doi.org/10.3390/toxins5101698
- ↑ 5.0 5.1 5.2 5.3 doi: https://dx.doi.org/10.1016/s0014-5793(00)01325-9
- ↑ 6.0 6.1 Fabbrini MS, Katayama M, Nakase I, Vago R. Plant Ribosome-Inactivating Proteins: Progesses, Challenges and Biotechnological Applications (and a Few Digressions). Toxins (Basel). 2017 Oct 12;9(10). pii: toxins9100314. doi:, 10.3390/toxins9100314. PMID:29023422 doi:http://dx.doi.org/10.3390/toxins9100314
- ↑ 7.0 7.1 Zhang GN, Gupta P, Wang M, Barbuti AM, Ashby CR Jr, Zhang YK, Zeng L, Xu Q, Fan YF, Chen ZS. Lipid-Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo. Cancers (Basel). 2020 Feb 21;12(2). pii: cancers12020498. doi:, 10.3390/cancers12020498. PMID:32098067 doi:http://dx.doi.org/10.3390/cancers12020498
- ↑ 8.0 8.1 doi: https://dx.doi.org/0.1073/pnas.0911606106
- ↑ 9.0 9.1 9.2 9.3 Zuppone S, Assalini C, Minici C, Bertagnoli S, Branduardi P, Degano M, Fabbrini MS, Montorsi F, Salonia A, Vago R. The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP. Sci Rep. 2020 Feb 13;10(1):2521. doi: 10.1038/s41598-020-59313-8. PMID:32054892 doi:http://dx.doi.org/10.1038/s41598-020-59313-8
